Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.70 |
| ▸ | FLT1 | P17948 | 4/20 | 0.70 |
| ▸ | KDR | P35968 | 4/20 | 0.69 |
| ▸ | CDK1 | P06493 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CCND3 | P30281 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 2/20 | 0.54 |
| ▸ | CLK3 | P49761 | 2/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514228 | 0.94 | KDR (0.63) | FGFR1FLT1KDRCDK1RET | |
| SCHEMBL15868925 | 0.85 | FGFR1 (0.80) | FGFR1FLT1KDRPDGFRAFGFR2 | |
| SCHEMBL3542101 | 0.85 | FGFR1 (0.80) | FGFR1FLT1KDRPDGFRAFGFR2 | |
| SCHEMBL4035837 | 0.83 | KDR (0.67) | FGFR1FLT1KDRCDK1RET | |
| SCHEMBL14906539 | 0.83 | FGFR1 (0.90) | FGFR1FLT1KDRPDGFRAFGFR2 | |
| SCHEMBL3536992 | 0.83 | FGFR1 (0.73) | FGFR1FLT1KDRRETPDGFRA | |
| SCHEMBL5513117 | 0.81 | MAP3K8 (0.63) | FGFR1FLT1KDRCDK1ERBB2 | |
| SCHEMBL3535921 | 0.81 | FGFR1 (0.76) | FGFR1FLT1KDRPDGFRAFGFR2 | |
| SCHEMBL31006250 | 0.81 | FGFR1 (0.76) | FGFR1FLT1KDRPDGFRAFGFR2 | |
| SCHEMBL3536819 | 0.80 | FGFR1 (0.71) | FGFR1FLT1KDRPDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | FGFR1 583/4885FLT1 2074/4885KDR 2231/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | FGFR1 254/4885FLT1 1117/4885KDR 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.